444-93-9

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide is utilized as an intermediate in the synthesis of various drugs. Its unique structure, which includes a trifluoromethylphenyl group and an oxyimine functional group, makes it a valuable component in the development of new pharmaceuticals. N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide's properties allow it to contribute to the creation of innovative medications, enhancing the range of treatments available for various health conditions.

Upstream product

• 302-17-0 chloral hydrate 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 75-87-6 chloral 
• 3792-04-9 2-chloro-N-[2-(trifluoromethyl)phenyl]acetamide 

Downstream Products

• 391-12-8 7-trifluoromethylisatin 
• 1075753-27-3 2-chloro-4-(trifluoromethyl)-1H-benzo[d]imidazole 
• 2251-78-7 4-(trifluoromethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 74396-78-4 7-Trifluoromethylisatin β-oxime 
• 313-12-2 2-amino-3-(trifluoromethyl)benzoic acid 
• 50419-85-7 2-amino-5-bromo-3-(trifluoromethyl)benzoic acid 

Relevant academic research and scientific papers

Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof

The invention discloses a benzenesulfonamide compound represented by a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. Compared with the prior art, the benzenesulfonamide compound disclosed by the invention can be used as an isocitrate dehydrogenase 2 (IDH2) mutant inhibitor. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibiting effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process of catalyzing alpha-ketoglutaricacid to generate 2-hydroxyglutaric acid by mIDH2, and can be used for preventing and/or treating various related diseases including cancers and the like caused by IDH2 mutation.

New Synthesis of 2-Oxoalkanamide Oximes

Reactions of α-halocarboxylic acid amides with 3 equiv of hydroxylamine hydrochloride in the presence of bases involves formation of products of nucleophilic substitution of the halogen atom and their subsequent oxidation to the corresponding oximes. This

Design, synthesis and insecticidal activities of novel anthranilic diamides containing fluorinated groups as potential ryanodine receptors activitors

In order to search for novel potent and environmentally benign insecticides, a series of anthranilic diamides containing various fluorinated groups were designed and synthesized. Their structures were confirmed by 1H NMR, 13C NMR, s

Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases

DYRK kinases are involved in alternative pre-mRNA splicing as well as in neuropathological states such as Alzheimer's disease and Down syndrome. In this study, we present the design, synthesis, and biological evaluation of indirubins as DYRK inhibitors wi

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

SUBSTITUTED INDOLE DERIVATIVES

Provided herein are indole derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

A modified Sandmeyer methodology and the synthesis of (±)-convolutamydine A

(±)-Convolutamydine A (5) has been prepared by it concise synthesis from 3,5-dibromoaniline using a modified Sandmeyer methodology. The modified Sandmeyer methodology has also been found to be beneficial for the synthesis of other α-isonitrosoacetanilides. The 4,6-dibromohydroxyoxindole nucleus was further confirmed by comparison with the isomeric 5,7-dibromohydroxyoxindole.